Teva To Pay $2.25 Million To Resolve Missouri Pollution Allegations

Source: Dow Jones News Service, March 14, 2013
Posted on: http://envfpn.advisen.com

Generic-drug maker Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) will pay $2.25 million to settle allegations its plant in Missouri broke environmental laws over a period of years, including by releasing pollutants that discolored part of a nearby river, the U.S. Justice Department said.
The Israel-based company was accused of violating federal clean-air and clean-water laws and hazardous waste laws at its facility in the city of Mexico, Missouri, officials said.
A representative from Teva, which is the world’s biggest manufacturer of generic drugs, wasn’t immediately available for comment.
In 2007, inspectors from the Environmental Protection Agency found that Teva’s facility was discharging pollutants above permitted levels, overwhelming the city’s ability to treat its domestic sewage, officials said. In 2008, the company was found to be releasing a green effluent that changed the color of the Salt River in late 2008.
Teva also failed to control its air pollution emissions from its wastewater in 2007, the Justice Department said.
And in 2009, state regulators found that the company failed to identify hazardous waste, illegally stored it, and offered it for transport without proper documentation.
“With numerous violations over a period of years, Teva’s actions resulted in significant environmental damage to the air and water,” said Karl Brooks, administrator of EPA Region 7.
Half of Teva’s penalty will be paid to the U.S. Treasury, while the other half will be paid to the state of Missouri.
The company has also agreed to take other actions valued at around $2.5 million, including installing equipment to reuse around 59.5 tons of methylene chloride and reduce its other emissions.
Teva has benefited from surging growth in recent years as patents expire on many high-demand pharmaceuticals.
Growing competition has pressured many generic drug makers’ margins, and Teva’s fourth-quarter earnings fell 37% to $ 320 million, amid weaker sales of generic drugs and lower overall sales in the key U.S. market.
Shares closed at $41.06 on Thursday and were unchanged after hours. The stock is up 10% since the start of the year.
 

Find a Broker or Underwriter

Search by product, location or name
SEARCH BY PRODUCT
---
Agribusiness
Aviation
Binding Authority
Builder's Risk
Casualty
Commercial Umbrella / Excess
Construction
Cyber
DIC
Defense Based Act
Earthquake
Energy
Environmental
Environmental & Construction Professional
Excess
Farm & Ranch
Flood/Earthquake
Garage
Healthcare
Healthcare
Inland Marine
Life Sciences
Marine
Occupational Accident
Package
Personal Lines
Personal Lines Farm & Ranch
Personal Lines – QuickHome
Personal Standard Lines
Personal Umbrella / Excess
Pollution
Private Client
Private Equity
Product Recall
Professional & Executive Liability
Property
Public Entity
Railroad
Real Estate
Shared Economy
Standard Lines
Surety
Surety
Transactional Liability & Private Equity
Transportation
Workers' Compensation
SEARCH BY LOCATION
---
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District Of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
https://www.insurancebusinessmag.com/us/best-insurance/best-wholesale-brokers-usa--5star-wholesale-brokers-and-mgas-478736.aspxhttps://www.newsweek.com/rankings/most-loved-workplaces-2024https://premium.insurancebusinessmag.com/us-iba-top-insurance-employers-2024-ryan-specialty/p/1

Please Update Your Browser

Unfortunately Microsoft is no longer providing support or security fixes for your web browser. RT Specialty values the safety and security of its clients’ data, and as such this site requires the use of a modern web browser. To update your web browser, please see the links below. If you have any questions or would like additional information, please email info@rtspecialty.com or call (312) 784-6001.

Firefox Firefox Chrome Chrome IE Internet Explorer Edge Microsoft Edge